Discussion
The U.S. Food and Drug Administration (FDA) has given the go-ahead for a mid-stage clinical trial testing the oral therapy forazapadin — designed to protect muscles and potentially enhance their regeneration — in adults with facioscapulohumeral muscular dystrophy (FSHD), marked by muscle weakness that particularly affects the face,…